MJN Neuroservices

What MJN Neuroservices does

MJN Neuroservices (legal: MJN NEUROSERVEIS, S.L.) is a privately-held Spanish medical device company founded in 2014/2015 and headquartered in Blanes, Girona. The company designs and manufactures AI-powered wearable earpieces that monitor brain electrical activity through the ear canal (ear-EEG) to predict epileptic seizure risk in real time. Its flagship product, mjn-SERAS, is a custom-fitted ear-mold device with embedded sensors paired with a mobile app, certified as a CE Class IIa medical device under EU MDR 2017/745 and UKCA Class IIa, with clinically validated performance of 96% sensitivity and 94% specificity. The technology is also being extended into Alzheimer's early detection through the DREAMER project (CDTI Misiones-funded) and the RETECH-backed mjn-BRiAN clinical decision support tool, with the outpatient mjn-VISOR EEG Holter system rounding out a broader neurological wearable portfolio.

The company operates a three-pronged revenue model: direct-to-consumer hardware sales of mjn-SERAS (priced in Euros with bundled mobile app), recurring annual maintenance subscriptions (Bronze / Silver / Gold tiers offering 2, 5, or unlimited algorithm re-personalizations per year), and licensing of the EPISERAS® brand to Neuraxpharm for pan-European commercial distribution starting H2 2026. Sales are currently executed through the mjn.cat e-commerce site in Spain, with availability extended to the UK and Netherlands via direct channels, while customers must complete an online eligibility test and visit an audioprotesist center for ear-mold customization. The go-to-market combines this D2C motion in Spain with enterprise channel-partner motion via Neuraxpharm across Europe, supported by clinical validation partnerships with Oxford University Hospital, Diakonie Kork, and Clínica Universidad de Navarra under the EIT Health consortium grant.

MJN is sustained by a portfolio of non-dilutive grants — including Horizon 2020 SME Instrument Phase 2 (€850K), CDTI Misiones (€1.44M+), and EIT Health Start-up Amplifier (€2.76M) — totaling well over €5M, alongside ENISA and Ship2B/Capital Cell participation. The 8-person team is led by CEO and co-founder David Blánquez, with a chief medical officer (Dra. Gloria Durán), CTO (Xavier Raurich), and an advisory board providing AI (PhD Beatriz López), neurology (Dr. Luismi Aras of Apoyo Dravet), and healthcare network expertise (Adrián Trejo of Neurociencias Corachan). The company has accumulated over 20 industry and innovation awards, including the WSA Global Champion for best digital health project in the world, and holds the Segell PYME Innovadora designation from the Spanish Ministry of Science, Innovation and Universities.

Name

MJN Neuroservices

Legal name

MJN NEUROSERVEIS, S.L.

Website

https://mjn.cat

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

MJN Neuroservices develops AI-powered wearable earpieces (mjn-SERAS / EPISERAS®) that monitor brain activity through the ear canal to predict epileptic seizure risk in real time, serving patients with drug-resistant epilepsy in Spain, the UK, and the Netherlands with planned pan-European expansion via Neuraxpharm.

Ownership category

akta.pro rank

Product category

Wearable Neurological Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)

Keywords

• Wearable medical devices
• Seizure prediction technology
• Ear-EEG monitoring
• Epilepsy management solutions
• AI neurology devices

Headquarters

HQ city

Girona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. mjn-SERAS Medical Device Sales: One-time sale of the mjn-SERAS wearable medical device (earpiece + mobile app). The product is sold as a combined unit — the earpiece cannot be purchased separately from the companion mobile app. Price is set on the website in Euros (VAT and delivery costs included). Currently sold in Spain with European expansion planned.
2. Annual Maintenance Plans (Bronze / Silver / Gold): Recurring annual subscription plans (Bronze, Silver, Gold) that provide algorithm re-personalization (2, 5, or unlimited times per year respectively), access to seizure reports, and software updates. First 1–2 years of maintenance included with device purchase. Without a maintenance plan, device reliability degrades over time.
3. EPISERAS® Licensing to Neuraxpharm: Partnership with Neuraxpharm for European commercialization of EPISERAS® (the same core technology branded differently). Neuraxpharm is a European pharmaceutical company specializing in CNS disorders, providing distribution and market access across Europe.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels9 records

Core offering

MJN Neuroservices designs, manufactures, and commercializes AI-powered wearable medical devices for neurological disease management. Its flagship mjn-SERAS product is a CE-certified Class IIa custom-fitted earpiece that continuously monitors brain electrical activity through ear canal sensors and uses personalized AI algorithms to predict epileptic seizure risk minutes in advance, alerting patients via a companion mobile app. The company also develops mjn-VISOR for outpatient EEG monitoring and DREAMER for early Alzheimer's detection using AI and EEG.

Product overview

MJN Neuroservices develops a portfolio of AI-powered wearable medical devices for neurological disease management. The core product is mjn-SERAS, a CE-certified Class IIa wearable earpiece that continuously monitors brain electrical activity via ear canal sensors and uses AI algorithms to predict seizure risk, paired with a mobile app. Under the EPISERAS® brand (distributed via Neuraxpharm partnership), the same technology reaches European markets. Supporting products include mjn-VISOR for outpatient EEG monitoring and DREAMER for Alzheimer's early detection using AI and non-invasive EEG recordings. The Social-SERAS companion app enables daily seizure tracking and data sharing with healthcare providers.

Differentiator

Problem solved

Functional benefit

Brands

• mjn-SERAS: A support system for people with epilepsy - a wearable earpiece that monitors brain activity and predicts seizure risk using AI algorithms
• DREAMER
• mjn-VISOR
• EPISERAS

Products and services

• mjn-SERAS Wearable medical device earpiece that continuously monitors brain electrical activity through ear canal sensors and uses AI algorithms to predict and alert users to epileptic seizure risk in real-time. Sold as a combined unit with a companion mobile app. CE Class IIa certified medical device for patients with drug-resistant epilepsy.
• EPISERAS® Commercial digital health solution branded for distribution by Neuraxpharm. AI-powered wearable earpiece device for early detection of epileptic seizures. CE Class IIa and UKCA Class IIa certified. Target: patients with drug-resistant epilepsy across Europe.
• mjn-VISOR System for monitoring brain activity in an outpatient/ambulatory setting. EEG Holter register device using portable, discrete, and non-invasive wearables allowing patients to perform daily activities while recording brain electrical activity comfortably.
• DREAMER Project for early detection and monitoring of Alzheimer's disease using AI techniques and non-invasive EEG recordings. Development of a portable, non-invasive wearable device with cognitive markers for early diagnosis of Alzheimer's in pre-clinical phase, targeting 12–18 months earlier than current diagnostic standards.
• Social-SERAS App Free companion mobile application for daily epilepsy management. Allows users to track seizure records and daily activities organized in calendar format. Enables sharing of data with neurologists for quick visualization of epilepsy evolution and patterns. Includes community features.
• Annual Maintenance Plans (Bronze / Silver / Gold) Recurring annual subscription plans providing algorithm re-personalization (Bronze: 2x/year, Silver: 5x/year, Gold: unlimited per year), access to seizure reports, and software updates. Required for maintaining device prediction accuracy over time.

Quantifiable outcome

• 96% sensitivity and 94% specificity in seizure prediction
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Partnerships

20 partnerships are on record, tiered flagship, core and minor.

• NeuraxpharmflagshipChannel Partner/ Reseller/ Distributor · 27 November 2025Strategic partnership for pan-European commercialization of EPISERAS® — the AI-powered seizure detection wearable developed by mjn-neuro. Neuraxpharm, a leading European CNS pharmaceutical company, will distribute EPISERAS® across Europe starting H2 2026. The partnership leverages Neuraxpharm's established neurology prescribing networks and pharmaceutical sales infrastructure. MJN-neuro initiated collaboration with Neuraxpharm in 2022.
• ACCIÓ (Generalitat de Catalunya)coreStrategic or Co-development Partner · 1 January 2025Catalan government innovation agency providing grant support for mjn-BRiAN project (AI-driven clinical decision support tool for Alzheimer's detection) and 2020 innovation voucher program for Alzheimer detection prototype development (Expediente ACE008/20/000316).
• ELAUSA ELECTRONICA I AUTOMATISMES S.L.minorStrategic or Co-development Partner · 1 January 2025Technology partner in the CDTI Misiones DREAMER project for early Alzheimer's detection using AI and EEG technology.
• INSTITUTO MEDICO PRIVADO S.L.P.minorStrategic or Co-development Partner · 1 January 2025Medical institution partner in the CDTI Misiones DREAMER project contributing clinical validation for Alzheimer's early detection using AI and EEG.
• WEIRD KIN S.L.minorStrategic or Co-development Partner · 1 January 2025Technology company partner in the CDTI Misiones DREAMER project for Alzheimer's early detection combining EEG and AI technologies.
• FEMenGIN (Udg)minorStrategic or Co-development Partner · 1 January 2025Gender diversity in engineering initiative at the Polytechnic School of the University of Girona. MJN supports women engineers and participates in roundtables promoting gender diversity in technology careers.
• Oxford University Hospital NHS Foundation TrustcoreStrategic or Co-development Partner · 1 January 2022UK hospital partner within the EIT Health Start-up Amplifier Instrument consortium (Grant 220445) focused on 'Improving Quality of Life for People with Epilepsy in Europe'. Contributing clinical validation expertise and UK market access for mjn-SERAS.
• Clínica Universidad de NavarracoreStrategic or Co-development Partner · 1 January 2022Spanish hospital partner in the EIT Health consortium. Collaborating on clinical validation of mjn-SERAS and European market preparation for the device.
• Diakonie KorkcoreStrategic or Co-development Partner · 1 January 2022German healthcare institution partner in the EIT Health consortium contributing to European clinical validation and market access for mjn-SERAS in Germany.
• Medical Valley (Germany)coreStrategic or Co-development Partner · 1 January 2022German medical technology cluster partner in the EIT Health consortium, supporting MJN's market entry and ecosystem integration in Germany.
• Biocat (Catalonia)coreStrategic or Co-development Partner · 1 January 2022Catalan biocluster supporting the EIT Health consortium and MJN's ecosystem integration in the Catalonia health innovation network.
• IESE Business SchoolcoreStrategic or Co-development Partner · 1 January 2022Spanish business school partner in the EIT Health consortium providing strategic business advisory, go-to-market strategy, and market expansion expertise for European scaling.
• Fundación DKV IntegraliacoreStrategic or Co-development Partner · 1 January 2022Spanish healthcare foundation partner in the EIT Health consortium supporting social impact and patient community engagement for the epilepsy device.
• Hospital Ruber Internacional de MadridcoreStrategic or Co-development Partner · 1 January 2022Collaborating on the EPISOFT clinical validation study expanding from 30 to 50 patients. Contributed to algorithm validation for mjn-SERAS.
• eXiT Research Group (Universitat de Girona)coreTechnology or Integration · 1 January 2020Research collaboration under the Retos Colaboración program (RTC-2017-6701-1, FEDER-funded) for developing predictive methods from biomedical data. The eXiT group has extensive experience creating predictive models from biomedical data for the mjn-SERAS algorithm.
• ALCE (Apoyo Dravet)minorStrategic or Co-development Partner · 1 January 2020Spanish patient association for Dravet syndrome and related epilepsies. Collaboration on the Horizon 2020 Big Data project and webinar participation for patient education and community engagement.
• Ship2B (Impact Forum)minorStrategic or Co-development Partner · 1 January 2020Exhibitor at the VII S2B Impact Forum (Impact Expo), Spain's largest impact economy event with 3,000+ attendees, for visibility and community building in the impact/startup ecosystem.
• Corachan Neuroscience DirectorateminorStrategic or Co-development Partner · 1 January 2020Advisory board member Adrián Trejo serves as Director of Neurociencias Corachan, providing clinical and healthcare network connections in the Barcelona healthcare ecosystem.
• FEDE (Federación Española de Epilepsia)minorStrategic or Co-development Partner · 1 January 2020Spanish Epilepsy Federation. MJN participated in the III Research Fair on Epilepsy organized by FEDE to present mjn-SERAS to the epilepsy patient and professional community.
• D'Genes (Asociación de Enfermedades Raras)minorStrategic or Co-development Partner · 1 January 2020Rare disease association organizing the II National Epilepsy Congress where mjn-neuro presented the mjn-SERAS project to families and healthcare professionals.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Empatica: Empatica's Embrace / EpiMonitor is the most direct competitor to mjn-SERAS — a wearable for seizure detection, FDA-cleared, sold to the same drug-resistant epilepsy patient population. Both are AI-driven wearables designed for ambulatory seizure monitoring outside the clinic.
• Brain Sentinel: Brain Sentinel developed the SPEAC system, an FDA-cleared surface-EMG based seizure detection wearable. Comparable business model and patient population, though different signal modality (sEMG vs. EEG).

Emerging players

• Epitel: Epitel makes PEAT, a small wearable EEG sensor for seizure monitoring, closely aligned with MJN's EEG-based approach. Targets similar neurology use cases but with a different form factor (behind-the-ear patch vs. in-ear).
• iMediSync: iMediSync develops EEG-based screening/diagnostic tools for early detection of neurological conditions (including Alzheimer's and dementia). Highly relevant to MJN's DREAMER project, which applies a similar early-detection thesis via EEG.
• Zeto: Zeto offers a wireless, easy-to-wear EEG headset for ambulatory brain monitoring. Comparable in that it brings EEG out of the clinical lab into the patient's daily environment — overlapping with MJN's mjn-VISOR strategy.

Broad incumbents

• Ceribell: Ceribell is a broader neurodiagnostic incumbent with point-of-care EEG and AI-based brain monitoring. Not a direct seizure-prediction wearable, but operates in the same neurology and EEG-monitoring category and competes for hospital neuro-monitoring budgets.
• Compumedics: Compumedics manufactures EEG and sleep-diagnostic systems used in hospitals and research. Operates in the same neuro-monitoring space and could plausibly enter the ambulatory seizure-prediction wearable category where MJN plays.
• Brain Products: Brain Products is a leading European EEG hardware and software maker, based in Germany. Same category (EEG instrumentation) and overlapping European clinical/research customer base, though focused on research-grade systems rather than wearables.
• Nihon Kohden: Nihon Kohden is a large established player in neurodiagnostic instrumentation (EEG, EMG, ICU monitoring). A broad incumbent whose portfolio overlaps with MJN's clinical/EEG ambitions — relevant as a much larger potential competitor or acquisition target.

Regional players

• Bitbrain: Bitbrain is a Spanish/European EEG wearable platform for research and applied neuroscience. Closely comparable in form factor (wearable EEG) and home geography (Iberia/Europe), even though its focus is research/B2B rather than patient-direct seizure prediction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=UaTRLytuub4
• Xx.com/mjnneuroserveis

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MJN Neuroservices